1 / 19

Medical Innovation

Medical Innovation. WELCOME. SAFE HARBOR AGREEMENT.

taber
Download Presentation

Medical Innovation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medical Innovation WELCOME

  2. SAFE HARBOR AGREEMENT Forward-looking statements in this presentation are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of NU-MED PLUS, Inc.’s products, increased levels of competition for the company, new products and technological changes, the company’s dependence on third-party suppliers, and other risks detailed from time to time in the company’s periodic reports filed with the Securities and Exchange Commission.

  3. AGENDA MANAGEMENT TEAM PROXY VOTE APPLICATION OVERVIEW TECHNOLOGY PLATFORM OVERVIEW MOVING FORWARD OTC BB:NUMD

  4. MANAGEMENT MANAGEMENT TEAM

  5. JEFF ROBINS BILL MOON DR. CRAIG MORRISON President | CEO Director VP of Technology Director VP of Research Director TOM TAIT BRETT J. EARL M.D. KEITH MERRELL VP of Scientific Adv. Director CFO | Treasurer Secretary VP of Med. Mktg. Director CHARLES IVESTER M.D. PH. D. Medical Advisor

  6. NU-MED PLUS OVERVIEW • NU-MED Plus, Inc.(OTC BB:NUMD) is an emerging growth-early stage biotechnology company focused on the design, development, and commercialization of next generation inhaled Nitric Oxide (NO) delivery systems to address unmet needs in the medical community. • At NU-MED, our mission is to improve the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is needed. We strive to exceed expectations in terms of safety, efficacy, and value by focusing on the science, development, and commercialization of our innovations. NU-MED’s NO delivery technologies are investigational and not yet approved by regulatory authorities.

  7. APPLICATION OVERVIEW MANAGEMENT TEAM

  8. NITRIC OXIDE BENEFITS Reduces oxidation of LDL cholesterol (major component of plaque) Dilates blood vessels Reduces platelet stickiness Immune system response support Reduces multiplication of smooth muscle cells of the artery walls Reduces monocyte stickiness (prevents formation of plaque)

  9. MARKET DETAILS Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 8.8%. In 2017, therapeutic devices accounted for the largest share of the global respiratory care devices type market. The rising incidence of chronic diseases and growing geriatric population contributes to their largest share in respiratory care devices type market. The rising demand for cost effective devices, portable devices and the lack of awareness of respiratory conditions leading to a large underdiagnosed and undertreated population and the harmful effects of certain respiratory care devices on neonates are the major challenges in this market.

  10. POTENTIAL APPLICATIONS FOR NITRIC OXIDE ANNUAL CASES Neonatal Complications 1.3 million COPD 80 million Tuberculosis 8 million Malaria 216 million Chronic Wound Healing 6.5 million Stored Blood enhancement 13.6 million units in the US Traumatic Brain Injury 1.7 million in the US 52,000 deaths

  11. TECHNOLOGY PLATFORMS MANAGEMENT TEAM

  12. NEW DEVELOPMENTS Low environmental impact proprietary formulation for in situ generation of NO • Engagement in FDA 510K process working toward • ISO 1345 Quality System Certification. Common technology for nitric oxide delivery products (patent pending) Development of Commercial Research unit

  13. BENEFITS OF NEW TECHNOLOGY Greater nitric oxide dose delivery control Potentially simplifies FDA approval Simplified instrument training in multi-product installation Safety for patient and personnel Wide range of treatment times Low manufacturing costs

  14. NMP 200 HOSPITAL INO DELIVERY SYSTEM PATENT PENDING • Simple operation • Dose control does not use valves or injectors • Innovative and instinctive along with being low cost • System delivers a continuous intra-breathconcentration of therapeutic NO to patientswho are on a ventilator • Designed for accuracy of the delivered dose over the full range of anticipated doses • Med's Nitric Oxide delivery systems are investigational and limited by federal law to investigational use only. Our units will require testing and FDA approval prior to any commercial use.

  15. Clinical/Office UnitNMP 300 PATENT PENDING • Attachments specific for treatment • Uses proprietary formula or pressurized cylinder for NO generation • Availability in emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes • Simple Small and easily fits into office environment. • Single treatment dose control and indicator • Innovative and instinctive along with being low cost • Med's Nitric Oxide delivery systems are investigational and limited by federal law to investigational use only. Our units will require testing and FDA approval prior to any commercial use.

  16. LIGHTWEIGHT PORTABLE UNITNITRIC OXIDE DELIVERY SYSTEM PATENT PENDING • Practical outside of the hospital setting for emergency response teams to treat diverse pulmonary situations, trauma injuries and for applications in developing nations. • Delivers high purity NO to the patient at prescribed intervals for 24 hours per day by means of a nasal cannula or a face mask. • Delivery dose can be adjusted from 2 to 40 PPM • Rechargeable/ 48 hour battery powered backup • Med's Nitric Oxide delivery systems are investigational and limited by federal law to investigational use only. Our units will require testing and FDA approval prior to any commercial use.

  17. Commercial NO Delivery UnitNMP 100 PATENT PENDING • Dilution range 1 – 500 ppm • Uses 100% pressurized Nitric Oxide cylinders • Nitrogen dioxide scrubber assures pure NO at instrument outlet • Designed for research to accommodate variable NO concentration needs • Cost effective source of ppm NO • The NMP 100 is the one of the world’s first nitric oxide dilution systems designed for research. A patent pending technology utilizes pure 100% nitric oxide from a pressurized tank source and dilutes it with air or other non-reactive diluent gas to provide a 1 to 500 ppm source of high purity nitric oxide for investigational applications. • No FDA approval required

  18. OBJECTIVES MOVING FORWARD MANAGEMENT TEAM

  19. OBJECTIVES MOVING FORWARD To increase exposure and expand shareholder value • Rebrand NU-MED PLUS- Website overhaul targeting investors. • Joined QTXQB (more efficient trading site) Q1 2018 • Engaged FDA Consultant Q1 2018 • Engage Public Relations and Investor Relations Firms Q2 2018 • Market NMP 100 (Commercial NO Unit) Q2 2018 • Attend/present at Medical trade shows/Conferences 2018 • File Patents in Q2,Q3,Q4,2018 (1 approved,2 pending) • Attain ISO 13485 QS certification 2018 (FDA requirement) • File FDA 510k for NMP 200( hospital unit) Q1 2019 • Evaluate commercial unit in agriculture research for increasing ripening and food quality.

More Related